Graves Disease Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, NICE Approvals, Prevalence, and Companies by DelveInsight

Graves' Disease Companies are Apitope International NV, Quintiles Inc., European Commission, Immunovant Sciences GmbH, Novartis Pharmaceuticals, AV7 Limited, Medtronic, Pfizer, Sanguine Biosciences, Tourmaline Bio Inc., Horizon Pharma USA Inc., Viridian Therapeutics Inc., Innovent Biologics Co. Ltd, Hoffmann-La Roche and others.
(Albany, USA) DelveInsight's "Graves' Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Graves' Disease, historical and forecasted epidemiology as well as the Graves' Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Graves' Disease Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Graves' Disease Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

The Graves' Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Graves' Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Graves' Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Graves' Disease market.

Unlock detailed insights into the Graves' Disease Market by downloading the comprehensive report from DelveInsight @ Graves' Disease Treatment Market Size [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Key Takeaways from the Graves' Disease Market Report

* In January 2025, Sling Therapeutics, Inc., a late-stage biopharmaceutical company developing an oral small molecule therapy for thyroid eye disease, announced topline results on the efficacy and safety of linsitinib from the Phase IIb/III LIDS trial in patients with active, moderate to severe TED.
* In September 2024:- Immunovant Sciences GmbH- A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED). To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
* In September 2024:- Amgen- The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period. The main objective of the study is to evaluate the effect of teprotumumab subcutaneous administration versus placebo on the proptosis responder rate (ie, the percentage of participants with a greater than or equal to 2-mm reduction from Baseline in the study eye without deterioration [ greater than or equal to 2-mm increase] of proptosis in the fellow eye) at Week 24.
* As per DelveInsight's estimates, Graves' disease is the primary cause of hyperthyroidism, responsible for 60-80% of cases. Despite this prevalence, it is relatively uncommon, impacting roughly 1.2% of the US population.
* According to American Thyroid Association (2024), more than 12% of the US population will develop a thyroid condition during their lifetime and an estimated 20 million Americans have some form of thyroid disease. Women are five to eight times more likely than men to have thyroid problems.
* As per data from the National Institute of Diabetes and Digestive and Kidney Diseases (2021), Graves' disease affects nearly 1 in 100 Americans.
* According to Shang et al. (2024), an estimated 2.7-3.0% of the adult Chinese population-over 31 million individuals-are affected by one or more autoimmune diseases, a prevalence comparable to that seen in Western populations. The predominant contributors to this burden are autoimmune thyroid diseases and rheumatoid arthritis.
* The leading Graves' Disease Companies such as Apitope International NV, Quintiles Inc., European Commission, Immunovant Sciences GmbH, Novartis Pharmaceuticals, AV7 Limited, Medtronic, Pfizer, Sanguine Biosciences, Tourmaline Bio Inc., Horizon Pharma USA Inc., Viridian Therapeutics Inc., Innovent Biologics Co. Ltd, Hoffmann-La Roche and others.
* Promising Graves' Disease Therapies such as linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.

Gain a competitive edge in the Graves' Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Graves' Disease Treatment Drugs [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Graves' Disease Epidemiology Segmentation in the 7MM

* Graves' Disease Gender-specific Cases
* Total Graves' Disease Prevalent Cases
* Graves' Disease Age Group-specific Cases
* Total Graves' Disease Treated Cases

Graves' Disease Market Insights

Graves' disease, an autoimmune disorder and the leading cause of hyperthyroidism, characterized by symptoms such as weight loss, rapid heartbeat, and in some cases, thyroid eye disease. While traditional treatments like anti-thyroid medications, radioactive iodine therapy, and thyroidectomy remain the cornerstone of management. Anti-thyroid drugs, such as methimazole and propylthiouracil (PTU), are commonly used to suppress thyroid hormone production, with Methimazole being the preferred first-line therapy due to its efficacy and safety profile. Radioactive iodine therapy is favored in the United States, especially when drug therapy is ineffective or contraindicated. It induces hypothyroidism, requiring thyroid hormone replacement. However, it is not recommended for patients with Graves' ophthalmopathy or smokers due to potential risks.

Discover key developments and opportunities in the Graves' Disease Market. Click here to learn more from DelveInsight's latest report @ Graves' Disease Market Size [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Graves' Disease Treatment Market

The DelveInsight's Graves' Disease treatment market report gives a thorough understanding of Graves' Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. The Graves' Disease treatment market has experienced significant growth and evolution in recent years, reflecting the increasing prevalence of Graves' disease, an autoimmune disorder that affects the thyroid gland. The Graves' Disease treatment market has witnessed the advent of innovative treatment modalities, including anti-thyroid drugs, radioactive iodine therapy, and surgery

Graves' Disease Companies and Therapies

* Sling Therapeutics, Inc.: linsitinib
* Immunovant Sciences GmbH: Batoclimab
* Amgen: Teprotumumab
* Viridian Therapeutics Inc.:- VRDN-001 10 mg/kg
* Hoffmann-La Roche: Satralizumab

Download DelveInsight's Graves' Disease Market report today and stay ahead in this rapidly evolving field. @ Graves' Disease Clinical Trials and FDA Approvals [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of the Graves' Disease Market Report

* Coverage- 7MM
* Graves' Disease Companies- Apitope International NV, Quintiles Inc., European Commission, Immunovant Sciences GmbH, Novartis Pharmaceuticals (SWX: NOVN), AV7 Limited, Medtronic (NYSE: MDT), Pfizer (NYSE: PFE), Sanguine Biosciences, Tourmaline Bio Inc. (NASDAQ: TRML), Horizon Pharma USA Inc., Viridian Therapeutics Inc. (NASDAQ: VRDN), Innovent Biologics Co. Ltd (HKEX: 1801), Hoffmann-La Roche (SWX: RO), and others.
* Graves' Disease Therapies- linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.
* Graves' Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Graves' Disease Unmet Needs, KOL's views, Analyst's views, Graves' Disease Market Access and Reimbursement

Download the report to understand which factors are driving Graves' Disease Market Dynamics @ Graves' Disease Market Trends [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Content

1. Key Insights

2. Graves' Disease Executive Summary

3. Competitive Intelligence Analysis for Graves' Disease

4. Graves' Disease: Market Overview at a Glance

5. Graves' Disease: Disease Background and Overview

6. Patient Journey

7. Graves' Disease Epidemiology and Patient Population

8. Graves' Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Graves' Disease Unmet Needs

10. Key Endpoints of Graves' Disease Treatment

11. Graves' Disease Marketed Products

12. Graves' Disease Emerging Therapies

13. Graves' Disease: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Graves' Disease Market Outlook

16. Graves' Disease Market Access and Reimbursement Overview

17. Graves' Disease KOL Views

18. Graves' Disease Market Drivers

19. Graves' Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graves-disease-treatment-market-2034-ema-pdma-fda-approvals-clinical-trials-medication-therapies-nice-approvals-prevalence-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.